The Neighborhood Is the Drug
Investing in programmable cell‑interaction communities over genes, cells, and “virtual cells.”
TL;DR
The real unit of action is a neighborhood, not a gene. Tumor outcomes hinge on cellular communities, not on isolated mutations or “virtual cells.”
Back the stack: measure → predict → modulate. Measure communities reliably; predict them cheaply; modulate them with therapies that reshape the neighborhood.
Measure (Ecosystem OS). Standardize community labels so results travel across labs and platforms; publish simple, blinded comparisons to prove the calls are portable.
Predict (proxies that scale). Use H&E slides and, where useful, cfDNA to infer community states fast and at low cost, with routine “truth checks” against spatial assays to stay calibrated.
Modulate (network‑aware drugs). Design interventions that change the micro‑ecology, improving priming, opening access, reducing suppression, and sustaining productive niches, rather than just pushing a single receptor.
Prove it in human tissue first. Show that a candidate actually reshapes the community in live human tumor samples before spending big on animal models or long trials.
Run adaptive, safety‑aware trials. Pair early tissue readouts with quick blood markers to stop futile paths and favor short pulses or sequencing when toxicity risks rise.
Make the economics work. Operate proxy‑first with periodic spatial truthing so decisions land in days at hospital‑friendly costs; keep spatial as the calibration and mechanism engine.
Own the calibration bridge. The moat is standards, datasets, and QA that keep proxies honest across sites, this is the “rails” every sponsor will need.
Build the portfolio, not a monolith. Invest in the rails (standards/calibration, proxy platforms, trial engines) plus one or two community‑modulating assets, and release capital in tranches tied to clear evidence gates.
The consensus worldview in oncology is still organized around atoms: first the gene, then the single cell, and most recently the “virtual cell” reconstructed from multiplex data. A long time ago, that hierarchy has produced real breakthroughs, but nowadays, it is the wrong unit of action for most solid tumors. Outcomes pivot on neighborhoods: multicellular communities of immune, stromal, vascular, and malignant cells that coordinate, or fail to, within spatially constrained micro‑ecologies. If you want durable response, you must measure, predict, and modulate these communities, not just tune a receptor or rebalance a cell state. That is the contrarian thesis. It is also an investable one, because it comes with hard evidence gates, visible operating moats, and a pragmatic regulatory and payer story.
The shift begins with an uncomfortable truth: a tumor’s behavior is topological. The same cells and genes produce different outcomes depending on who sits next to whom, how signals diffuse through matrix and vasculature, and, for example, whether dendritic cells can license T cells inside the tumor rather than at its margins. Spatial biology didn’t just add pretty pictures; it turned these neighborhoods into measurable objects. Once neighborhoods are measurable, they can be named, standardized, tracked across centers, and, most importantly, deliberately perturbed. The practical implication is stark. If you are underwriting a program that treats the cell as the terminal unit of action, you are pointing your telescope at the wrong star.
The critique of “virtual cells” follows from the same logic. Reconstructing fine‑grained cell states with deconvolution or single‑cell embeddings is useful for discovery, but it rarely captures the interaction grammar that governs outcome. Two tumors with near‑identical virtual cell catalogs can diverge clinically because one assembles licensing micro‑niches where antigen‑presenting cells and helper T cells coordinate with cytotoxic effectors, while the other is dominated by fibroblast lattices, hypoxic rims, and suppressive myeloid corridors. In the former, access and priming are solved problems and checkpoint release has something to work with. In the latter, it does not. The map, not the roster, separates responders from non‑responders.
Once you accept that the neighborhood is the right unit, an operating model falls out: measure, predict, and modulate communities in a loop that learns quickly and spends frugally (unlike recent big funding rounds that regularly fail to produce impressive outputs). Measurement means a portable “Ecosystem OS,” a standardized way to call multicellular communities, sometimes called ecotypes, across platforms and laboratories with ring‑trial‑grade concordance. Investors should treat portability as a gating criterion. If a community label cannot reproduce across vendors and sites with high agreement, it will not survive contact with pivotal trials or payer scrutiny. The minimum bar is not rhetorical; it is quantitative. Agreement rates need to look like real diagnostics, not research curiosities. In practice, that means overall percent agreement comfortably in the eighties or better across independent laboratories on pre‑specified datasets. Anything less forces platform lock‑in and costly bridging studies, which is a tax on optionality.
Prediction is where the economics flip. Tissue‑heavy spatial assays are powerful but expensive and slow if you try to run them at scale. The unlock is proxy learning: using whole‑slide histopathology foundation models and, in some settings, cfDNA signatures to infer community labels and risk strata quickly and cheaply. The proxies do not need to be perfect; they need to be calibrated. The standard to underwrite is parity within striking distance of spatial “ground truth” (think area‑under‑the‑curve in the low‑eighties) paired with explicit drift monitoring and periodic spatial truthing on a subset of cases. That calibration loop is not a side quest; it is the moat. Without it, proxies will overfit to a site, a scanner, or a staining protocol and silently lose signal in exactly the places where decision value is highest. With it, you get the only combination that matters in operations: low cost, fast turnaround, and fidelity sufficient to drive enrichment and sequencing decisions in real trials.
Modulation completes the loop. If the unit of action is a community, then drugs must be designed to change community topology, not just receptor occupancy. That does not require mystical new chemistry. It means network‑aware therapeutics (non‑CD3 multispecifics, stromal and vascular modulators, and context‑specific cytokine or chemokine programs) deployed to push four levers that consistently appear in spatial maps: priming, access, suppression, and positive niche support. Priming increases the formation and persistence of antigen‑presenting and helper niches that can license effectors inside the tumor. Access dismantles the physical and metabolic barriers (fibroblast nets, abnormal vessels, hypoxia) that keep killers out. Suppression relief silence the myeloid and regulatory circuits that broadcast “don’t attack.” Positive niche support maintains the neighborhoods that already correlate with benefit, allowing de‑intensification rather than escalation. This is the vocabulary that translates a spatial map into a therapy plan.
The clinical translation of community modulation must start in human tissue. That is not a slogan; it is a way to avoid years of beautifully controlled failures. The best early proof‑of‑mechanism does not come from an animal tumor that does not share our micro‑ecology; it comes from live human tumor slices and organotypic cultures where you can measure whether a candidate intervention actually remaps the neighborhood. Three tissue‑native readouts make these experiments decisive. First, a community remodeling index that summarizes movement from unproductive to productive community states. Second, a suppression score that reflects myeloid, regulatory, and adenosine‑like features declining in response to treatment. Third, adjacency metrics that capture whether effectors are coming into contact with the right support cells in the right places at the right time. If those move in a meaningful way across a majority of donor tissues (say, a two‑fold shift in the composite and robust changes in adjacency), then you have a drug worth spending on.
Trial design in a community‑first world becomes mercifully pragmatic. You do not need to wait for overall survival to learn whether you have a signal. You pre‑register a chain of evidence that links early tissue pharmacodynamics to short‑horizon clinical markers such as ctDNA and response assessments, and you combine that with toxicity gates that keep patients safe when community modulation risks spillover. Adaptive protocols that include window‑of‑opportunity tissue sampling and blood‑based early futility rules are not academic luxuries here; they are the operating system of capital efficiency.
The economics, which often get hand‑waved in platform pitches, are central to why the thesis is investable. Spatial assays will not replace H&E and multiplex IF in every community hospital any time soon. They do not have to. If your stratification flow is proxy‑first with truthing on a subset, your costs and turnaround times fall into ranges that sponsors, health systems, and payers will accept. A mature operation can deliver proxy calls in days and reserve spatial for calibration, edge cases, and mechanistic studies that seed the next generation of interventions. The resulting blended cost per decision and time‑to‑decision are what unlock scale. Investors should insist that teams present this as a real operating plan, with calibration budgets, not as a future nice‑to‑have.
The market structure that follows is not monolithic; it is a stack. At the base, companies that own the ecosystem dictionary and its calibration earn durable fees because everyone else depends on them. Above that, proxy platforms that turn histopathology and cfDNA into calibrated community calls capture the margin that comes from speed and scale. Sitting beside them, trial engines that operationalize human‑in‑the‑loop designs become the default partners for sponsors exploring combinations and sequences. And at the top, community‑modulating therapeutics benefit from the entire infrastructure by knowing whom to treat, when to switch, and how to read out success early.
Skeptics will raise three serious objections. The first is cross‑platform variance: if different spatial technologies disagree on community calls, how can any of this generalize? The answer is governance. Public, blinded ring trials with predefined endpoints, reference tissues, and published pipelines are the only antidote. If a platform cannot clear agreement thresholds across independent laboratories, the right move is to lock a primary platform for a specific indication, escrow tissue for bridging, and keep moving. The second objection is proxy drift: if the foundation model looks great in one hospital and degrades in another, isn’t this a mirage? Again, the antidote is explicit calibration. Proxies are living models, not static code. You allocate a budget and a cadence for truthing against spatial subsets, monitor performance by site and cohort, and retrain conservatively. The third objection is toxicity: community modulation sounds like combination therapy, and combinations have a way of hurting patients. This is where design matters. Short pulses rather than long doublets, pre‑specified toxicity gates, and sequencing based on early signals are the design choices that turn a mechanistic idea into a clinically responsible plan.
What should operators do in the next quarter if they believe this thesis? They should design one human‑tissue program that proves they can actually remodel a neighborhood and make that the gating milestone for additional spend. And they should write statistical analysis plans that connect community change to early outcomes before the first patient is enrolled, so that investors, regulators, and payers can follow the logic without reverse‑engineering it from a poster.
The deepest reason to back community‑first oncology is physics. Genes and single cells are necessary coordinates, but they are not sufficient to explain or change how tumors live and die inside bodies. The geometry of interactions, the “where” and “with whom”, sets the constraints within which molecular programs play out. A useful analogy is urban planning. You can analyze every resident in exquisite detail and still miss why a city thrives or fails if you ignore its streets, services, and zoning. Spatial biology finally gave oncology the zoning map. The companies that learn to read it, simulate it with economical proxies, and re‑zone it safely will bend clinical trajectories and cash flows in the same motion.
If we look five years out, the pattern will be obvious in hindsight. Community labels will be routine exploratory endpoints in phase 2 oncology. A handful of spatial assays will secure narrow selection claims where they clearly outperform older biomarkers, but most scale will come from calibrated proxies that deliver answers in days for a fraction of the cost. Trial designs will bake in tissue pharmacodynamics and blood‑based early futility, so that learning happens in weeks rather than years. New drug classes will be described by the communities they modulate rather than by their receptors alone. Standards organizations and proficiency programs will be revenue‑generating businesses, not volunteer committees. And the companies that compound value fastest will be the ones that treat communities as the actionable unit from day one.
The contrarian bet, then, is not to abandon molecular precision but to place it inside the right topology. Stop pretending that a better list of genes or a higher‑resolution pseudo‑cell will save you from the neighborhood you refuse to measure. Start underwriting teams that can make communities portable, make proxies honest, and make interventions change the living geometry of tumors in human tissue before they ask you for the next check. In oncology, as in cities, the unit of action is the neighborhood. Invest accordingly.